Explore

Trendline Trendline
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders

Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expanding into Metabolic Disorders
Trendline Trendline
FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls

FDA Reversals in Rare Disease Trials Highlight Challenges with External Controls
Trendline Trendline
Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm Files Class Action Against Aldeyra Therapeutics Over Misleading Statements
Trendline Trendline
Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights

Takeda Ends Partnership with Denali Therapeutics, Returns Dementia Drug Rights
Trendline Trendline
Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline

Rosen Law Firm Urges Corcept Therapeutics Investors to Act Before Class Action Deadline
Trendline Trendline
Pharma M Activity Surges with Record Highs Anticipated in 2026

Pharma M Activity Surges with Record Highs Anticipated in 2026

Pharma M Activity Surges with Record Highs Anticipated in 2026
Trendline Trendline
Fortuna Mining Schedules Annual Shareholders’ Meeting for June 2026

Fortuna Mining Schedules Annual Shareholders’ Meeting for June 2026

Fortuna Mining Schedules Annual Shareholders’ Meeting for June 2026
Trendline Trendline
Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans

Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans

Immunovant's Batoclimab Fails Phase 3 Trials, Impacting Thyroid Eye Disease Treatment Plans
Trendline Trendline
Robbins Geller Rudman Dowd LLP Announces Class Action Against ImmunityBio for Securities Violations

Robbins Geller Rudman Dowd LLP Announces Class Action Against ImmunityBio for Securities Violations

Robbins Geller Rudman Dowd LLP Announces Class Action Against ImmunityBio for Securities Violations
Trendline Trendline
MP Materials Faces Investor Scrutiny Over Texas Magnet Project and Insider Sales

MP Materials Faces Investor Scrutiny Over Texas Magnet Project and Insider Sales

MP Materials Faces Investor Scrutiny Over Texas Magnet Project and Insider Sales
Trendline Trendline
President Trump's Platform to Feature New Weight Loss Drug, Expanding Access for Consumers

President Trump's Platform to Feature New Weight Loss Drug, Expanding Access for Consumers

President Trump's Platform to Feature New Weight Loss Drug, Expanding Access for Consumers
Trendline Trendline
Eli Lilly Gains FDA Approval for Oral Weight-Loss Pill, Impacting Obesity Market

Eli Lilly Gains FDA Approval for Oral Weight-Loss Pill, Impacting Obesity Market

Eli Lilly Gains FDA Approval for Oral Weight-Loss Pill, Impacting Obesity Market